Valuation : Vaxart, Inc.

Market Cap 120M 103M 97.32M 88.9M 166M 11.35B 167M 1.15B 446M 5.82B 451M 442M 18.76B P/E 2026 *
-3.09x
P/E 2027 * -0.58x
Enterprise Value 120M 103M 97.32M 88.9M 166M 11.35B 167M 1.15B 446M 5.82B 451M 442M 18.76B EV / Sales 2026 *
1.01x
EV / Sales 2027 * 51.2x
Free-Float
98.56%
Yield 2026 *
-
Yield 2027 * -
1 day+0.63%
1 week+20.38%
Current month+18.41%
1 month+0.65%
3 months-2.09%
6 months-20.54%
Current year+74.34%
1 week 0.49
Extreme 0.49
0.62
1 month 0.46
Extreme 0.4608
0.62
Current year 0.34
Extreme 0.3434
0.84
1 year 0.3
Extreme 0.305
0.84
3 years 0.26
Extreme 0.2606
1.54
5 years 0.26
Extreme 0.2606
9.4
10 years 0.25
Extreme 0.2543
24.9
Manager TitleAgeSince
Chief Executive Officer 60 18/03/2024
Chief Tech/Sci/R&D Officer 59 01/03/2024
Director of Finance/CFO - 19/05/2025
Director TitleAgeSince
Director/Board Member 68 21/04/2021
Director/Board Member 76 04/08/2022
Director/Board Member 79 01/01/2022
Date Insider Type Main position Quantity % Market Cap. Importance
16/07/26 Free

Director

118,100 0.0488%
16/07/26 Free

Director

118,100 0.0488%
16/07/26 Free

Director

118,100 0.0488%
Change 5-day change 1-year change 3-year change Capi.($)
+0.63%+20.38%+60.31%-27.35% 120M
-1.79%-2.27%+50.90%+89.03% 69.02B
-2.06%-0.18%+41.53%+88.17% 66.32B
-0.31%+6.54%-11.39%+457.82% 27.66B
-3.00%-2.90%+39.40%+9.41% 26.54B
+0.86%+1.65%+0.25%-14.78% 25.84B
-1.46%+0.42%+24.07%-18.70% 20.4B
-2.96%-15.21%+210.71%+370.84% 17.63B
-1.49%-4.88%-0.41%+530.26% 15.15B
-0.20%+8.37%+57.87%+159.50% 14.65B
Average -1.18%-0.31%+47.32%+164.42% 28.33B
Weighted average by Cap. -1.53%-0.34%+42.56%+144.87%

Financials

2026 *2027 *
Net sales 119M 102M 96.02M 87.71M 164M 11.2B 165M 1.13B 440M 5.75B 445M 436M 18.51B 2.35M 2.02M 1.9M 1.74M 3.25M 222M 3.26M 22.48M 8.72M 114M 8.82M 8.63M 367M
Net income -47.2M -40.62M -38.21M -34.91M -65.3M -4.46B -65.48M -452M -175M -2.29B -177M -173M -7.37B -222M -191M -179M -164M -307M -20.92B -307M -2.12B -823M -10.73B -832M -814M -34.58B
Net Debt - -
Logo Vaxart, Inc.
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. The Company’s development programs include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), its first immune-oncology indication. The Company's platform technology employs a vector-based approach and consists of various components, such as vector, antigen, and adjuvant. A vector is a virus used as a carrier to deliver DNA coding for vaccine antigens and an adjuvant selected to activate the immune system. An antigen is a viral or bacterial protein that stimulates an immune response to the targeted pathogen.
Employees
65
Date Price Change Volume
04/09/26 $0.4950 +0.51% 130,592
03/09/26 $0.4925 +0.41% 256,912
02/09/26 $0.4905 -0.51% 252,589
01/09/26 $0.4930 -3.33% 262,462
31/08/26 $0.5100 +1.66% 221,455
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.4950USD
Average target price
3.333USD
Spread / Average Target
+573.40%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VXRT Stock